Deutsche Bank Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $28
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsInitiationPrice Target
Deutsche Bank analyst David Hoang initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $28.
Deutsche Bank analyst David Hoang initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $28.